Vyne Therapeutics Inc
NASDAQ:VYNE

  • LAST PRICE
    3.0300
  • TODAY'S CHANGE (%)
    0.1300 (4.4828%)
  • Bid / Lots
    2.7500/ 1
  • Ask / Lots
    3.1800/ 1
  • Open / Previous Close
    2.8800 / 2.9000
  • Day Range
    2.8800
    3.1200
  • 52 Week Range
    1.5700
    4.0900
  • Volume
    67,653

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 18, 2024

  • Nov 8, 2024

  • Nov 7, 2024

      Show headlines and story abstract

    • 8:04AM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: VYNE
      08:04 AM EST, 11/07/2024 (MT Newswires) -- ...

    • 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: VYNE

      Third-party products and company names mentioned herein may be the trademarks of their respective owners.
      VYNE THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) (Unaudited) September 30, December 31, --------------- ---------------- 2024 2023 ---------- --------- Assets Current Assets: Cash and cash equivalents $ 16,272 $ 30,620 Restricted cash 47 54 Investment in marketable securities 53,913 62,633 Prepaid and other current assets 3,303 2,656 Total Current Assets 73,535 95,963 ---------- --------- Non-current Assets: Operating lease right-of-use assets 122 207 Non-current prepaid expenses and other assets 2,541 1,515 Total Non-current Assets 2,663 1,722 ---------- --------- Total Assets $ 76,198 $ 97,685 ========== ========= Liabilities and Stockholders' Equity Current Liabilities: Trade payables $ 3,986 $ 1,659 Accrued expenses 6,168 4,119 Employee related obligations 1,071 1,645 Operating lease liabilities 123 115 Other current liabilities 1,313 -- ---------- --------- Total Current Liabilities 12,661 7,538 Long-term Liabilities: Non-current operating lease liabilities -- 99 Other liabilities -- 1,313 ---------- --------- Total Long-term Liabilities -- 1,412 ---------- --------- Total Liabilities 12,661 8,950 ---------- --------- Commitments and Contingencies Stockholders' Equity: Preferred stock: $0.0001 par value; 20,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 -- -- Common stock: $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 14,751,433 and 14,098,888 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1 1 Additional paid-in capital 782,650 780,044 Accumulated other comprehensive income 34 26 Accumulated deficit (719,148) (691,336) ---------- --------- Total Stockholders' Equity 63,537 88,735 ---------- --------- Total Liabilities and Stockholders' Equity $ 76,198 $ 97,685 ========== ========= VYNE THERAPEUTICS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------- ---------------------- 2024 2023 2024 2023 ------ ------- Revenues Royalty revenues $ 121 $ 114 $ 417 $ 348 ------- ------ ------- ------- Total Revenues 121 114 417 348 ------- ------ ------- ------- Operating Expenses: Research and development 10,248 3,318 21,262 13,284 General and administrative 2,964 3,030 10,022 9,490 Total Operating Expenses 13,212 6,348 31,284 22,774 ------- ------ ------- ------- Operating Loss (13,091) (6,234) (30,867) (22,426) Other income, net 934 163 3,074 706 ------- ------ ------- ------- Loss from continuing operations before income taxes (12,157) (6,071) (27,793) (21,720) Income tax expense -- -- -- -- ------- ------ ------- ------- Loss from continuing operations (12,157) (6,071) (27,793) (21,720) Loss from discontinued operations, net of income taxes -- (513) (19) (544) ------- ------ ------- ------- Net Loss $(12,157) $(6,584) $(27,812) $(22,264) ======= ====== ======= ======= Loss per share from continuing operations, basic and diluted $ (0.29) $ (1.85) $ (0.65) $ (6.66) ======= ====== ======= ======= Income (loss) per share from discontinued operations, basic and diluted $ 0.00 $ (0.16) $ 0.00 $ (0.17) ======= ====== ======= ======= Loss per share, basic and diluted $ (0.29) $ (2.01) $ (0.65) $ (6.82) ======= ====== ======= ======= Weighted average shares outstanding - basic and diluted 42,587 3,282 42,592 3,271 ======= ====== ======= =======

Peers Headlines